Connect with us

Industry

First meeting of UK Cannabis Industry Council lays groundwork for “real change”

Stakeholders from across the sector have set out their agenda for creating a more robust UK industry

Published

on

Members of the newly-formed Cannabis Industry Council met for the first time this week. Photo: Sam Cannon

Stakeholders from across the industry met for the first time at the inaugural meeting of the newly-formed Cannabis Industry Council. 

Members of the Cannabis Industry Council (CIC), which launched officially last month, met in London on Wednesday 7 July to set out how they plan to create a more robust UK sector.

More than 100 major organisations have now joined the body, which aims to set standards and drive meaningful change within the UK’s medical cannabis and CBD space. 

The meeting was one of the industry’s first in-person events to take place since the coronavirus pandemic hit last March.

Representatives from more than half the members travelled to be there as the council’s various subgroups, including Research, Hemp, Environment, Social and Governance (ESG), Standards Parliamentary Lobbying and Media, Marketing & PR set out their agenda for moving forward. 

CIC chair, Prof Mike Barnes (right) with Hemp chair Jamie Bartley and secretary Kate Thorpe

Major focuses for research include building a strong scientific case for the use of medicinal cannabis, through real-world evidence and condition-specific research, as well as economic and health cost-benefit analysis. 

There will also be a drive to see the removal of the current licensing framework around industrial Hemp as a controlled drug and a transition of responsibility from the Home Office to DEFRA. The group will also call for the UK THC limit to be raised for industrial hemp, and an allowance for the whole plant to be utilised. 

The introduction of an Office of Medical Cannabis within the UK Government was highlighted as a key lobbying priority, along with patient access, while discussion took place around the development of a set of standards across the industry and the introduction of a code of conduct for all suppliers, dispensers and advertisers, patients and consumers. 

READ MORE  Cannabis company offsets 25,956 tonnes of emissions to become carbon neutral

Professor Mike Barnes, founder and chair of the CIC said it was great to be “up and running” and that the response to the initial meeting indicated there was potential to make “real change” as a collective voice for the sector.

From left: Secretary Kate Thorpe, Research chair Anne Katrin Schlag and Prof Mike Barnes. Photo: Sam Cannon

“It was really exciting to see so many people come along to the first meeting of the CIC,” Prof Barnes commented.

“There was some very promising and exciting proposals and ideas set out by the various subgroups, which illustrates just how important and wide ranging out agenda is in the development of the cannabis sector in the UK and the impact this will have on so many industry stakeholders and so many patients.”

He added: “There was a lot of good interaction and good discussion and it was great to see so many representatives from different parts of the industry coming together in such a way.

“Now that the CIC is up and running, we can begin to work towards our shared goal of creating a robust cannabis sector in the UK.”

Find out more about the CIC

Industry

The Sisters of CBD giving away free hemp seeds in the US

The Sisters of the Valley have become renowned for growing organic high-CBD hemp plants.

Published

on

Sisters of the Valley
Home » Industry » First meeting of UK Cannabis Industry Council lays groundwork for “real change”

Self-formed order and CBD producers, Sisters of Valley, are giving away 1,000 free packets of hemp seeds to customers in California.

Known in the media as ‘weed nuns’ or the ‘sisters who make CBD’, Sisters of the Valley is a self-formed new age order of women based in the Central Valley of California, USA.

The women have become renowned for growing organic high-CBD hemp plants and producing homemade infused CBD oil which they ship across the world.

Sisters of the Valley: Hemp and CBD seeds

Now, to celebrate the arrival of spring, the sisters are giving away souvenir hemp seed packets, to 1,000 US customers who have shopped in their recently-launched online store. 

They hope to start send 500 packets in February, followed by another 500 in March.

Those customers will receive a thank card, along with their packet of seeds. 

Sister Kate said: “Worried about Covid, economic collapse, global warming, supply chain issues, un-compassionate governments?  So are we! Learn to grow your own food and medicine. It’s healing in itself just to be doing something.”

The seeds will be primarily distributed to American customers.

Sister Sophia, explained: “We aren’t shipping internationally because, firstly, there won’t be a lot of them since our international sales have fallen from 20 per cent to three per cent during Covid.  And secondly, we don’t want to get anyone in trouble.  We will reach out to those international customers and see if they want us to mail them before we 

READ MORE  Ireland medical cannabis survey finds 'overwhelming' support for reform

do.”

Sisters of Valley Community

The sisters describe themselves as ‘beguine revivalists with influences from the Indigenous Tribes of California’. They also live, work and pray together. While they refer to themselves as order and are called sisters, the group is not affiliated with the Catholic church or any other religion.

Their mission is to get plant-based medicines to those in need. The order work on their own farm to produce high-CBD hemp products including balms and oils.

In 2019 Breaking Habits, a documentary film about Sister Kate was released. It received an award at the London Cannabis Film Festival.

For more industry news visit cannabiswealth.co.uk

 

 

Continue Reading

Industry

New global platform offers affordable cannabis education

New online courses are set to offer low-cost, reliable, cannabis education.

Published

on

cannabis education
Canadian education platform, Edusity, has partnered with the Pharmacology University

A new online education platform is set to tackle stigma around cannabis and open up opportunities for learners across the globe.

Canadian education platform, Edusity, has partnered with the Pharmacology University of Texas-based CHNC, to help learners assess the risks, benefits and business opportunities that come with cannabis legalisation.

Cannabis may be a legal product in Canada, but there are still barriers to learning about the plant, according to Edusity’s founders.

The online education platform enables instructors to post self-directed, video-based courses and to teach live webinars via its virtual classroom. Pharmacology University is another online educational platform which aims to transform the social stigma around medicinal cannabis.

“Education really is the best tool for addressing every area of social change,” said Vishal Shah, co-founder of Edusity. 

“In the past, there have been difficulties communicating about legal cannabis education, but with the use of age gate technology and other safeguards, Edusity is helping to create a culture of cannabis literacy that is essential to building a stable, safe industry.”

There are currently 12 low-cost courses from Pharmacology University’s programme available on Edusity.com ranging from cannabis and obesity to cannabis dispensary operations.

Anne Graham, CEO of Pharmacology University, commented: “Pharmacology University is pleased to partner with Edusity on the delivery of our program. As the legalisation of cannabis spreads around the world, there is a need for clear, honest and expertise-driven education about the herb itself, the medical science, the legislation and the business that moves it. We are pleased to have Edusity work with us to make Cannabis education happen.”

READ MORE  Medical cannabis education platform showcased by RCP

Continue Reading

Industry

71% of CBD consumers see improvement in wellbeing

3,000 people took part in the ‘first of its kind’ study

Published

on

Report: A CBD oil bottle and products

Results from what is thought to be the largest study to date, show over 70 per cent of CBD consumers saw improvements to their wellbeing.

The study, carried out by Radicle Science, involved over 3,000 participants who were given CBD products to try at home.

The organisation’s Advancing CBD Education and Science (ACES) report, aimed to determine the effectiveness of botanical CBD products.

The randomised controlled trial involved 13 US brands and examined different reasons for taking CBD. This included wellbeing, quality of life, pain, anxiety and sleep quality.

Report: A banner advert for Always Pure Organics CBD business support

The results revealed that 71 per cent of participants saw an improvement in well-being, with 63 per cent seeing a ‘clinically meaningful improvement in anxiety. A further 61 per cent reported an improvement in sleep quality while 47 per cent said their pain levels were decreased.

Sixty one per cent of participants reported feeling the effects of the CBD within one to four hours of consuming their chosen products.

CBD report

Speaking with Cannabis Health,  Jeff Chen, CEO and co-founder said: “There are studies of American consumers showing that millions are using CBD yet despite that, we still don’t know a lot about it. One of the key reasons is that it was lumped together with cannabis for the longest time so if you wanted to study these products then it was near impossible. What little understanding we have comes mainly from cell and animal studies which shows some amazing things.”

He added: “When we talk about human studies of CBD then there is so little data. The main reasons people are using it is for pain, sleep, stress and anxiety. So our job, as Radicle Science was to generate a body of knowledge and understanding to help consumers.”

The result was a ‘first of its kind’ study providing real-world data on CBD use.

It examined how people used CBD in their own homes rather than a medical setting, how much they use and also what side effects they experienced. To do this, the researchers gathered a diverse pool of participants and paired them with different brands. As the products were mailed to consumers, the study wasn’t limited to those who live near a laboratory and as a result, 3,000 people took part.

READ MORE  CBD 'not effective' for cocaine addiction - but there's still potential for other cannabinoids

Jeff said: “We wanted to involve a variety of different brands with a variety of formulations but we also wanted a diverse pool of participants. This included people from different geographies, ethnicities and demographics to make this as ‘real world’ as possible. We mailed the products to people to take in their own home.”

Report: ACES study into CBD use

The success of the CBD was measured with different scientific scales. These findings were assessed through five indices: the World Health Organization (WHO)-5 Well Being Index, the Kemp QOL scale, the Generalised Anxiety Disorder (GAD)-7 scale, the Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance SF 8B scale, and the PEG-3 Scale for pain.

Jeff said: “When we were assessing the outcomes, we used measures that were developed by the World Health Organisation or the US National Institue of Health for sleep or pain. We collected all of these validated survey instruments along with tonnes of information on demographics, behaviour and health conditions. we want to understand if there are any variables, whether ethnicity or caffeine consumption may affect usage.”

He added: “As we were working with the brands, we knew exactly what products they were taking and what was in them. Our study made calculating the dosage really easy too, which can be really difficult for consumers. We had participants report how many servings they were using whether that is a gummy or a capsule. The bottle is very clear about what each serving is. We have the chemical analytic results, we can back-calculate the dosage to give us a normalised dosage data.”

READ MORE  Weightlifter, Jenny Tong: “I'm proud of my body and how hard it works”

Radicle Science report results

The study reported significant improvements in the three main areas people reported using CBD for, such as pain, sleep and anxiety.

Jeff said: “We found that depending on what health outcome you are looking at, 47 to 63 per cent of people experienced not just an improvement but a clinically meaningful one. This means that they are experiencing changes to sleep quality or anxiety that is large enough to make a healthcare provider say it is meaningful. It’s strong enough that it deserves to be further utilised.

Another interesting result was that a majority of people reported the impact within several hours of taking the product. We are still trying to figure out the mechanism of action for CBD. It appears that one of the mechanisms seems to be affecting the serotonin system. If you look at things like SSRIs that are prescribed for anxiety, then they can take several weeks to kick in. What we saw was the onset of effects from CBD happening within several hours.”

Jeff highlighted that the study also examined the participant’s quality of life and wellbeing, which may have seen an improvement due to decreased anxiety and sleep problems. The next phase will examine more of the data points from the study.

He said: “We will be doing a lot more sophisticated biostatistics. The next stage will examine the role that demographic or behavioural characteristics may have played or if they had predictive effects on the outcomes. For example, is the use of caffeine or alcohol made you more or less likely to experience an effect. Did ethnicity mean you were more likely to experience a positive outcome?

“We will look at the different product attributes for the 13 brands to see if a gummy had an advantage over a tincture for example. There is still a lot to be determined that will come in the next wave of analysis.”

READ MORE  “I woke up feeling happy for the first time in a long while

report: A row of three bottles of oil sitting on a shelf with a cannabis plant in the background

Prospect Farms entered some of its products into the ACES study.

Speaking with Cannabis Health, CEO Brad Tipper explained how beneficial the study has been for the brand.

“Our focus has been creating terpene-forward products,” said Brad.

“It makes Prospect Farms products unique in the market compared to a lot of our peers. Our balance products which were included in the ACES study are great for mood and cognition. This was a great opportunity for us to be able to differentiate our view of the market right now. We wanted to be able to show the difference in using quality carriers or terpene blends for health outcomes.”

He added: “One of the biggest areas we hoped Radicle Science would shine a light on is consumer behaviour around dosing. Tinctures are still a very unique concept for the broader audience. We are used to taking a supplement or an over the counter product but we are not used to holding something on our tongues for 30 seconds. Thinking about pipettes and graduated marks can be an intimidating concept.”

CBD report and product changes

Brad highlighted that the insights into dosing have been incredibly valuable for the brand. They have been able to take this into consideration when it comes to their products.

He said: “It has informed a lot of our product development considerations. We are restricted in terms of what we can do under current regulations and we can’t make explicit dosage recommendations. We can allow you to understand how much is in each one of your doses and have direct consultations with the consumer. It has also highlighted a need for potentially higher strength products. This has informed some of our product development.”

Continue Reading

Trending